MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Genomics assays that measure specific gene expression patterns in a patient's primary tumor
have become important prognostic tools for breast cancer patients. This study is designed to
test the ability of MammaPrint® in combination with TargetPrint®, BluePrint®, and
TheraPrint®, as well as traditional pathologic and clinical prognostic factors, to predict
responsiveness to neo-adjuvant chemotherapy in patients with locally advanced breast cancer
(LABC).
Phase:
Phase 4
Details
Lead Sponsor:
Agendia
Collaborators:
AdventHealth Florida Hospital Morton Plant Mease Health Care Ohio State University Comprehensive Cancer Center Plano Cancer Center University of Miami University of Oklahoma University of South Alabama University of South Florida